Tengion, the good the bad and the ugly (posters included)
good points, but I have to disagree with #4. neo-kidney is interesting but public biotech companies rarely get credit for pre-clinical science projects. they may get credit in terms of IP and scientific know-how if a buyout ever comes, but that's a big 'if'.
NUC is also very far away from fda approval, and its success in trials is definitely not assured. and I think there's a good chance the FDA will require the company to re-do some animal studies before starting up again in humans.
if you want to buy the stock today, you have to be willing to take the risk of round after round of highly dilutive financing.
Redoing animal studies??? You are the first person to suggest that and with three human patients underway and being carefully monitored, there is no need to use an animal study to change a surgery technique for ensuring blood supply. Going back to animal studies are common with lack of data or adverse effects with pharmaceutical products, not in a trial like this. You need to tie that idea to a source, a real source, because I watch and listen to this stock carefully and that is totally coming from left field, which of course makes me wonder about it... but not too much because this is only the yahoo mb... my last post on this subject for a while, everyone keep their eyes open, a falling stock draws all sorts of folks to it, hoping for a carcass to make a few cents on so you will probably hear all sorts of things. On the other hand, the company will be disseminating real information, good or bad, I suspect in the coming months and we will see how the street values this new science... there are plenty of little pharmas out there with bigger market caps and much less to say for themselves so no use thinking too much about it. good luck.